Pharmacokinetics, safety, and tolerability of BMS‐986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment
Abstract BMS‐986263 is a retinoid‐conjugated lipid nanoparticle delivering small interfering RNA designed to inhibit synthesis of HSP47 protein, a collagen‐specific chaperone protein involved in fibrosis development. This is a phase I, open‐label, two‐part study evaluating pharmacokinetics and safet...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-10-01
|
| Series: | Clinical and Translational Science |
| Online Access: | https://doi.org/10.1111/cts.13581 |
| _version_ | 1797657454725562368 |
|---|---|
| author | Hisham Qosa Claudia H. M. C. deOliveira Giovanni Cizza Eric J. Lawitz Nicholas Colletti Jeffrey Wetherington Edgar D. Charles Giridhar S. Tirucherai |
| author_facet | Hisham Qosa Claudia H. M. C. deOliveira Giovanni Cizza Eric J. Lawitz Nicholas Colletti Jeffrey Wetherington Edgar D. Charles Giridhar S. Tirucherai |
| author_sort | Hisham Qosa |
| collection | DOAJ |
| description | Abstract BMS‐986263 is a retinoid‐conjugated lipid nanoparticle delivering small interfering RNA designed to inhibit synthesis of HSP47 protein, a collagen‐specific chaperone protein involved in fibrosis development. This is a phase I, open‐label, two‐part study evaluating pharmacokinetics and safety of BMS‐986263 in participants with hepatic impairment (HI). Part 1 (n = 24) of this study enrolled two cohorts with mild and moderate HI and a separate cohort of age‐ and body mass index (BMI)‐matched participants with normal hepatic function. Part 2 enrolled eight participants with severe HI and eight age‐ and BMI‐matched participants with normal hepatic function. All participants received a single intravenous 90 mg BMS‐986263 infusion. Compared with normal‐matched participants, geometric mean area under the plasma concentration‐time curve time zero to the time of the last quantifiable concentration (AUC(0‐T)) and AUC from zero to infinity (AUC(INF)) of HSP47 siRNA were similar in participants with mild HI and 34% and 163% greater in those with moderate and severe HI, respectively, whereas the maximum plasma concentration was ~25% lower in mild and moderate HI groups but 58% higher in the severe HI group than in the normal group. Adverse events were reported by two of eight, four of eight, and three of eight participants with mild, moderate, or severe HI, respectively; none were reported in the normal‐matched group. Overall, single‐dose BMS‐986263 was generally safe and well‐tolerated and dose adjustment is not considered necessary for participants with mild or moderate HI. Although available data do not indicate that dose adjustment should be performed in patients with severe HI; the optimal posology of BMS‐986263 in patients with severe HI may be determined later in its clinical development when additional data to establish exposure‐safety/efficacy relationship becomes available. |
| first_indexed | 2024-03-11T17:45:47Z |
| format | Article |
| id | doaj.art-4e63f1a38b104278b07475928f2d40b4 |
| institution | Directory Open Access Journal |
| issn | 1752-8054 1752-8062 |
| language | English |
| last_indexed | 2024-03-11T17:45:47Z |
| publishDate | 2023-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Science |
| spelling | doaj.art-4e63f1a38b104278b07475928f2d40b42023-10-18T07:31:18ZengWileyClinical and Translational Science1752-80541752-80622023-10-0116101791180210.1111/cts.13581Pharmacokinetics, safety, and tolerability of BMS‐986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairmentHisham Qosa0Claudia H. M. C. deOliveira1Giovanni Cizza2Eric J. Lawitz3Nicholas Colletti4Jeffrey Wetherington5Edgar D. Charles6Giridhar S. Tirucherai7Bristol Myers Squibb Princeton New Jersey USABristol Myers Squibb Princeton New Jersey USABristol Myers Squibb Princeton New Jersey USAThe Texas Liver Institute, University of Texas Health San Antonio San Antonio Texas USABristol Myers Squibb Princeton New Jersey USABristol Myers Squibb Princeton New Jersey USABristol Myers Squibb Princeton New Jersey USABristol Myers Squibb Princeton New Jersey USAAbstract BMS‐986263 is a retinoid‐conjugated lipid nanoparticle delivering small interfering RNA designed to inhibit synthesis of HSP47 protein, a collagen‐specific chaperone protein involved in fibrosis development. This is a phase I, open‐label, two‐part study evaluating pharmacokinetics and safety of BMS‐986263 in participants with hepatic impairment (HI). Part 1 (n = 24) of this study enrolled two cohorts with mild and moderate HI and a separate cohort of age‐ and body mass index (BMI)‐matched participants with normal hepatic function. Part 2 enrolled eight participants with severe HI and eight age‐ and BMI‐matched participants with normal hepatic function. All participants received a single intravenous 90 mg BMS‐986263 infusion. Compared with normal‐matched participants, geometric mean area under the plasma concentration‐time curve time zero to the time of the last quantifiable concentration (AUC(0‐T)) and AUC from zero to infinity (AUC(INF)) of HSP47 siRNA were similar in participants with mild HI and 34% and 163% greater in those with moderate and severe HI, respectively, whereas the maximum plasma concentration was ~25% lower in mild and moderate HI groups but 58% higher in the severe HI group than in the normal group. Adverse events were reported by two of eight, four of eight, and three of eight participants with mild, moderate, or severe HI, respectively; none were reported in the normal‐matched group. Overall, single‐dose BMS‐986263 was generally safe and well‐tolerated and dose adjustment is not considered necessary for participants with mild or moderate HI. Although available data do not indicate that dose adjustment should be performed in patients with severe HI; the optimal posology of BMS‐986263 in patients with severe HI may be determined later in its clinical development when additional data to establish exposure‐safety/efficacy relationship becomes available.https://doi.org/10.1111/cts.13581 |
| spellingShingle | Hisham Qosa Claudia H. M. C. deOliveira Giovanni Cizza Eric J. Lawitz Nicholas Colletti Jeffrey Wetherington Edgar D. Charles Giridhar S. Tirucherai Pharmacokinetics, safety, and tolerability of BMS‐986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment Clinical and Translational Science |
| title | Pharmacokinetics, safety, and tolerability of BMS‐986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment |
| title_full | Pharmacokinetics, safety, and tolerability of BMS‐986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment |
| title_fullStr | Pharmacokinetics, safety, and tolerability of BMS‐986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment |
| title_full_unstemmed | Pharmacokinetics, safety, and tolerability of BMS‐986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment |
| title_short | Pharmacokinetics, safety, and tolerability of BMS‐986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment |
| title_sort | pharmacokinetics safety and tolerability of bms 986263 a lipid nanoparticle containing hsp47 sirna in participants with hepatic impairment |
| url | https://doi.org/10.1111/cts.13581 |
| work_keys_str_mv | AT hishamqosa pharmacokineticssafetyandtolerabilityofbms986263alipidnanoparticlecontaininghsp47sirnainparticipantswithhepaticimpairment AT claudiahmcdeoliveira pharmacokineticssafetyandtolerabilityofbms986263alipidnanoparticlecontaininghsp47sirnainparticipantswithhepaticimpairment AT giovannicizza pharmacokineticssafetyandtolerabilityofbms986263alipidnanoparticlecontaininghsp47sirnainparticipantswithhepaticimpairment AT ericjlawitz pharmacokineticssafetyandtolerabilityofbms986263alipidnanoparticlecontaininghsp47sirnainparticipantswithhepaticimpairment AT nicholascolletti pharmacokineticssafetyandtolerabilityofbms986263alipidnanoparticlecontaininghsp47sirnainparticipantswithhepaticimpairment AT jeffreywetherington pharmacokineticssafetyandtolerabilityofbms986263alipidnanoparticlecontaininghsp47sirnainparticipantswithhepaticimpairment AT edgardcharles pharmacokineticssafetyandtolerabilityofbms986263alipidnanoparticlecontaininghsp47sirnainparticipantswithhepaticimpairment AT giridharstirucherai pharmacokineticssafetyandtolerabilityofbms986263alipidnanoparticlecontaininghsp47sirnainparticipantswithhepaticimpairment |